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Introduction
In vitro and in vivo experiments have demonstrated a
potent yet opposite effect of IL-2 on both regulatory
T cells (TREG) and IL-17+CD45RA-CD4+ T cells (Th17).
TREG cells have been implicated as an important immu-
noregulator enhancing tumor growth whereas Th17 cells
may mediate tumor destruction. This study compares the
effect of high-dose IL-2 (HDIL-2) on both the TREG and
Th17 compartments in responders and non-responders.
Methods
Peripheral blood was collected at baseline and at 24, 48,
72, and 96 hours post-treatment from 6 patients under-
going HDIL-2 therapy under an IRB approved protocol.
No patients enrolled received anti-PD-1 or anti-CTLA4
therapies. PBMCs were isolated and underwent intracel-
lular cytokine and extracellular receptor staining for
flow cytometry. Statistical analysis was performed using
paired student’s t tests via Prism 6.0e software.
Results
5 of 6 patients clinically progressed on HDIL-2 therapy
(non-responders, NR), and these patients demonstrated
an increase in the frequency of CD25+FoxP3+CD4+
T cells (TREG) on day 4 of treatment (4% +/- 1% on day
0 to 14% +/- 6% on day 4, p value = 0.06). A single
patient responded to HDIL-2 therapy (complete respon-
der, CR) and demonstrated a decrease in the frequency
of TREG cells on day 4 of treatment (9% on day 0 to 7%
on day 4). HDIL-2 increased the frequency of IL-17
+CD45RA-CD4+ T cells (Th17) on day 4 of therapy in
all patients analyzed (0.7% +/- 0.4% on day 0 versus 2%
+/- 1% on day 4, p value=0.04; Figure 1). Absolute num-
bers of Th17 cells also demonstrated a statistically
significant increase on day 4 of therapy (5 +/- 1 cell/µL
on day 0 versus 38 +/- 24 cells/µL on day 4, p
value=0.04, Figure 2). Subsequent analyses demonstrated
a negative Th17:TREG ratio on day 4 of HDIL-2 treatment
in all non-responders. Importantly, the complete respon-
der demonstrated a positive Th17:TREG ratio on day 4 of
treatment (Figure 3). The observed difference in cytokine
production appeared to be specific to IL-17 as there was
no statistically significant change in frequency or total
numbers of IFN-g+ or IL-2+CD4+ and CD8+ T cells.
Conclusion
Our results suggest a distinct immunophenotype indicative
of response to HDIL-2. Analysis of peripheral TREG and
Th17 cell frequencies early in the course of HDIL-2
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therapy may help identify those patients who would benefit
from subsequent cycles.
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